Why the study?
No drugs are currently available or in clinical trials to combat cardiac remodeling, and the role of transcription factors in cardiac remodeling remains largely unexplored.
Key points are not available for this paper at this time.
Design
Literature review
Answers are grounded in this paper and cite their sources.
Should not yet change practice; leaves open whether animal transcription-factor targeting can reverse remodeling in humans.
Transcription factors govern various functions in the cell such as proliferation, repair, regenerative programs, etc. Currently, there are no available drugs on the market or subjected to clinical trials that can combat cardiac remodeling. Understanding the role of transcription factors in cardiac remodeling may open the door to developing agents that can reverse structural remodeling of the heart and prevent heart failure. Recent studies shed light on the function of transcription factors involved in cardiac remodeling. Pharmacological modulation of signaling involving transcription factors may present as a novel mechanism for improving cardiac metabolism, promoting cardiac cell survival, etc. Various transcription factor-targeting agents were tested in animal models and showed promising results. Nevertheless, despite significant advances, the role of transcription factors in cardiac remodeling presents an extremely unexplored area. The main goal of this literature review was to summarize the latest advances made in our understanding of the role of transcription factors in cardiac remodeling and their potential to be used as molecular therapy targets.
No takes yet. Share an insight, caveat, or question.
Biswal et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: